ISI to feature Robert de Haan as eSolutions 2007 Keynote Speaker
Recognized Pharma Industry Innovators to speak at ISI Annual Conference
Whippany, NJ (August 7, 2007) – Image Solutions, Inc. (ISI), a leader in providing software and services to streamline the drug development lifecycle, today announced Mr. Robert de Haan, Deputy Director, Medicines Evaluation Board (MEB), in the Netherlands, will be their Keynote Speaker at their upcoming eSolutions 2007 Conference to be held in Lake Las Vegas October 8-10.
Mr. de Haan is currently responsible for the Registration, Information Processing, Management support and Facilities at the MEB.
Regulatory agencies in the European Union have targeted 2009 for the ability to accept regulatory submissions in the electronic common technical document (eCTD) format. The Medicines Evaluation Board (MEB) is well ahead of this schedule, and Mr. de Haan will provide a detailed update on the progress achieved thus far, the challenges encountered, and the future direction of electronic regulatory submissions at the Netherlands National Competent Authority.
eSolutions 2007, is an annual industry event that provides a powerful combination of informative and practical solution strategies for Life Science professionals. This conference is ISI’s 5th Annual eSolutions Conference and once again promises a full two day conference agenda that includes presentations and case studies from industry-leading organizations, luminaries and international regulatory experts.
The focus of the presentations is best practices in electronic submissions, paper and electronic clinical trials, and the system and process changes required to fully optimize today’s regulatory and clinical landscapes. Last year’s eSolutions Conference in New York City included presentations and case studies by leading Life Science organizations AstraZeneca, Novartis, Teva, Organon, NeurogesX, PDL Biopharm and Abraxis BioScience, Inc., among others.
The conference will be followed by a full day of user group meetings, providing insights and inviting audience participation in the future direction of ISI’s industry-leading solutions for achieving efficiencies in the drug development process.